KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Free Cash Flow (2016 - 2026)

Gsk has reported Free Cash Flow over the past 18 years, most recently at $2.1 billion for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 11.44% year-over-year to $2.1 billion; the TTM value through Mar 2026 reached $12.5 billion, up 17.95%, while the annual FY2025 figure was $8.5 billion, 28.52% up from the prior year.
  • Free Cash Flow for Q1 2026 was $2.1 billion at Gsk, down from $3.8 billion in the prior quarter.
  • Over five years, Free Cash Flow peaked at $5.6 billion in Q4 2023 and troughed at -$361.3 million in Q4 2022.
  • A 5-year average of $2.5 billion and a median of $2.6 billion in 2025 define the central range for Free Cash Flow.
  • Biggest five-year swings in Free Cash Flow: plummeted 110.42% in 2022 and later soared 1649.46% in 2023.
  • Year by year, Free Cash Flow stood at -$361.3 million in 2022, then soared by 1649.46% to $5.6 billion in 2023, then plummeted by 34.12% to $3.7 billion in 2024, then increased by 2.84% to $3.8 billion in 2025, then tumbled by 44.15% to $2.1 billion in 2026.
  • Business Quant data shows Free Cash Flow for GSK at $2.1 billion in Q1 2026, $3.8 billion in Q4 2025, and $3.4 billion in Q3 2025.